Turku, Finland, 18. May 2025
The Abomics team has been strengthened with a new addition, as MD Nora Nikander has joined our Medical Advisory team. She previously worked as a physician at Turku University Hospital. Nora has a strong interest in personalized medicine and pharmacogenetics, and she brings with her valuable clinical expertise.
In her role as Medical Advisor, Nora will contribute to the development and implementation of pharmacogenetic tools that support healthcare professionals in making safer, more individualized medication decisions. Her clinical insight will help ensure that our solutions remain practical, relevant, and truly beneficial for both doctors and patients.
About Abomics
Abomics collaborates with clinical laboratories, clinical research organizations, electronic health record (EHR) providers, genetics companies, and biobanks to deliver pharmacogenetic interpretation services and personalized pharmacogenetic reports. These tools help physicians select the most appropriate medication and dosage based on a patient’s genetic profile.
Abomics also develops medical and pharmaceutical databases that support clinicians in making informed prescribing decisions. In early 2025, Abomics completed its merger with Multirec, a company with over 20 years of experience in providing drug databases and clinical decision support for electronic health records. Multirec’s strong reputation and long-standing partnerships with leading EHR vendors enhance Abomics’ ability to integrate pharmacogenetics into routine clinical workflows in a user-friendly and effective way.
info(at)abomics.fi
+358 2 454 2500
Yliopistonkatu 31
20100 Turku, Finland
Abomics, Abomics PGx, GeneRx, GeneAccount are registered or non-registered trademarks of Abomics Oy in various countries.
